Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
Rival, M., Rollot, F., Laurent-Chabalier, S., Casey, R., El Bahi, I., Brocard, G., Marignier, R., Trouillet-Assant, S., Vukusic, S., Fromont, A., et al. (2026). Eur J Neurol (33). p.e70767

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
Zhu, C., Vukusic, S., Kalincik, T., Mathey, G., Kermode, A.G., Maillart, E., Lechner-Scott, J., Le Page, E., Roos, I., Ciron, J., et al. (2026). J Neurol Neurosurg Psychiatry p.jnnp-2026-339059

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis
Moukhine, A., Rollot, F., Casey, R., Collongues, N., Vukusic, S., Mathey, G., Dubessy, A.L., Ciron, J., De Seze, J., Ruet, A., et al. (2026). Ann Clin Transl Neurol

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
Roos, I., Sharmin, S., Horakova, D., Kubala Havrdova, E., Libertinova, J., Vachova, M., Alroughani, R., Boz, C., Rous, Z., Buzzard, K., et al. (2026a). J Neurol Neurosurg Psychiatry (97). p.763–773

External validation of KFLC index threshold for multiple sclerosis diagnosis in a French cohort
Aguesse, C., Micoud, E., Vukusic, S., Venet, F., Pescarmona, R., Monneret, G., Marignier, R., and Nicolas, P. (2026). J Neurol (273). p.469

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database
Carcaillon-Bentata, L., Abouelfath, A., Lignot-Maleyran, S., Lassalle, R., Jové, J., Blin, P., Berger, E., Bourre, B., Camdessanche, J.P., Casez, O., et al. (2026). Mult Scler Relat Disord (111). p.107209

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability
Sharmin, S., Roos, I., Labauge, P.M., Filippi, M., Lebrun-Frenay, C., Iaffaldano, P., Simone, M., Perini, P., Magy, L., Van Der Walt, A., et al. (2026). Neurology (106). p.e218056

Updated French OFSEP Recommendations for Multiple Sclerosis MRI: Alignment with the 2024 McDonald Criteria
Lecler, A., Mondot, L., Homo, C., Tourdias, T., Vukusic, S., Durand-Dubief, F., Bapst, B., and Cotton, F. (2026). Journal of Neuroradiology p.101576

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis
Rollot, F., Casey, R., Kerbrat, A., Edan, G., Le Page, E., Vukusic, S., Mathey, G., Maillart, E., De Sèze, J., Ciron, J., et al. (2026). Brain (149). p.2022–2031

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis
Benallegue, N., Rollot, F., Iaffaldano, P., Lucisano, G., Simone, M., Lugaresi, A., Casey, R., Cocco, E., Vukusic, S., De Luca, G., et al. (2026). Mult Scler p.13524585261446829

PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis
Demuth, S., Faddeenkov, I., Paris, J., Rousseau, O., Baciotti, B., Payet, M., Casey, R., Vukusic, S., Doyle, S., Jarre, G., et al. (2026). JAMIA Open (9). p.ooag039

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis
Gavoille, A., Kerbrat, A., Edan, G., Le Page, E., Rollot, F., Casey, R., Mathey, G., Stankoff, B., Ciron, J., De Seze, J., et al. (2026). Neurology (106). p.e214943

Performances of experts and automated methods on new multiple sclerosis lesions detection: insights from the MSSeg2 challenge
Masson, A., Combès, B., Kerbrat, A., Ardellier, F.-D., Rabaste, S., Cloarec, P., Wdowik, Q., Edan, G., Cervenansky, F., Casey, R., et al. (2026). Sci Rep (16). p.23247

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS
Tournier, A., Gavoille, A., Pique, J., Levraut, M., Micoud, E., Maillart, E., Audoin, B., Demortiere, S., Boutiere, C., Ayrignac, X., et al. (2026). Neurology (106). p.e214806

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
Roos, I., Sharmin, S., Ozakbas, S., Alroughani, R., Eichau, S., Grand’Maison, F., Boz, C., Lechner-Scott, J., Buzzard, K., Prat, A., et al. (2026b). CNS Drugs

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Boudot de la Motte, M., Gavoille, A., Papeix, C., Audoin, B., Ayrignac, X., Bourre, B., Ciron, J., Cohen, M., Collongues, N., Laplaud, D.A., et al. (2026). JAMA Neurol

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients
Comet, C., Jouvenot, G., Bourre, B., Ciron, J., Audoin, B., Ayrignac, X., Cohen, M., Deschamps, R., Durand-Dubief, F., Maillart, E., et al. (2026). Mult Scler (32). p.214–223

Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations
Ricigliano, V.A.G., Masmoudi, I., Boudot de la Motte, M., Manchon, E., and De Seze, J. (2026). Ther Adv Neurol Disord (19). p.17562864261458568